To accelerate new target discovery and translational medicine research, Arbele has established strong scientific collaboration with key opinion leaders (KOLs) from leading academic institutions and medical centers in Hong Kong, Beijing, Taipei, Rome (Italy), Stockholm (Sweden), Oxford (UK), and New York, San Diego, San Francisco, and Seattle in the USA. For GMP manufacturing of immunotherapeutics including CAR-T cells, the Company has formed strategic partnerships with China Regenerative Medicine International (8158.HK) which has facilities in Hong Kong, Xian and Suzhou. The Company also works with multiple contract research organizations like Covance and MedPace for clinical trial operations in HK, Asia and USA.
Arbele is positioned to be a leader in cancer immunotherapies for solid tumors. A central player in cancer immunotherapy is a type of white blood cell known as the T cell. In healthy individuals, T cells identify and kill infected or abnormal cells like tumors. However, cancer cells carrying the ability (especially in solid tumors) to evade immune surveillance is a key factor in their growth, spread, and persistence. We leverage two technologies - Chimeric Antigen Receptor (CAR) and Bi-specific Monoclonal Antibodies (BiMAbs) - to activate the patient's T cells so that they attack cancer cells.READ MORE